Skip to main content
AC

ATMA CENA Practitioners

This startup provides psilocybin-assisted therapy sessions aimed at enhancing mental health and personal empowerment. By facilitating guided experiences with this hallucinogen, individuals can achieve deeper self-connection and improved well-being.

Calgary, CanadaFounded 2020121K+ followers
Updated 18 months ago

Funding

$390K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

MC
Funding rounds are not available yet.

Founders

Product

Problem

Individuals seeking mental health support often face challenges in accessing effective treatments that address the root causes of their conditions, leading to reliance on medications that only manage symptoms or are ineffective for a significant portion of patients. The emerging field of psychedelic-assisted therapy holds promise but requires trained professionals and regulated environments to ensure safe and beneficial outcomes.

Solution

ATMA CENA Psychedelic Healthcare Solutions offers comprehensive psychedelic-assisted therapy and training programs designed to revolutionize access to mental health care. The company provides psychedelic therapy treatments, including assessment, drug administration, and monitoring. ATMA CENA also delivers training programs for healthcare practitioners, equipping them with the essential infrastructure and knowledge to administer psychedelic-assisted therapy effectively. Through a network of clinics and a focus on practitioner-centered care, ATMA CENA aims to increase accessibility to safe and effective psychedelic-assisted therapy, addressing the underlying causes of mental health conditions and promoting lasting well-being.

Target Audience

The primary target audience includes individuals seeking alternative mental health treatments, mental healthcare professionals looking to expand their practice with psychedelic-assisted therapy, and clinics aiming to offer innovative mental health solutions.

Features

  • Psychedelic-assisted therapy (PaT) using ketamine, with plans to include psilocybin and MDMA upon legalization
  • Comprehensive assessment of patients to determine suitability for PaT
  • Clinical trials to develop IP protocols and validate the effectiveness of group healing practices
  • Training programs for healthcare professionals, including in-person clinical training workshops on MDMA-assisted therapy utilizing the MAPS protocol
  • Clinic network and infrastructure for ATMA students to commence PaT delivery in safe, regulated facilities
  • Development of clinical protocols and training for ketamine-assisted therapy to treat addictions
  • Integration of traditional healing wisdom with evidence-based psychedelic therapies
This profile is AI-generated and may contain inaccuracies.